company background image
PBN logo

Alterity Therapeutics DB:PBN Stock Report

Last Price

€0.001

Market Cap

€13.2m

7D

-33.3%

1Y

-50.0%

Updated

04 Oct, 2024

Data

Company Financials +

Alterity Therapeutics Limited

DB:PBN Stock Report

Market Cap: €13.2m

PBN Stock Overview

Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.

PBN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Alterity Therapeutics Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Alterity Therapeutics
Historical stock prices
Current Share PriceAU$0.001
52 Week HighAU$0.01
52 Week LowAU$0.0005
Beta0.68
11 Month Change-33.33%
3 Month Change-50.00%
1 Year Change-50.00%
33 Year Change-92.59%
5 Year Change-92.86%
Change since IPO-98.70%

Recent News & Updates

Recent updates

Shareholder Returns

PBNDE BiotechsDE Market
7D-33.3%0.2%-1.0%
1Y-50.0%-9.9%12.8%

Return vs Industry: PBN underperformed the German Biotechs industry which returned -9.9% over the past year.

Return vs Market: PBN underperformed the German Market which returned 12.8% over the past year.

Price Volatility

Is PBN's price volatile compared to industry and market?
PBN volatility
PBN Average Weekly Movement88.7%
Biotechs Industry Average Movement6.2%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: PBN's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: PBN's weekly volatility has decreased from 364% to 89% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
199710David Stamleralteritytherapeutics.com

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer’s disease.

Alterity Therapeutics Limited Fundamentals Summary

How do Alterity Therapeutics's earnings and revenue compare to its market cap?
PBN fundamental statistics
Market cap€13.20m
Earnings (TTM)-€11.86m
Revenue (TTM)€2.49m

5.3x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PBN income statement (TTM)
RevenueAU$4.02m
Cost of RevenueAU$214.30k
Gross ProfitAU$3.80m
Other ExpensesAU$22.93m
Earnings-AU$19.12m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0036
Gross Margin94.67%
Net Profit Margin-475.79%
Debt/Equity Ratio0%

How did PBN perform over the long term?

See historical performance and comparison